Mr. Matthew W. Foehr, also known as Matt, has been the Chief Operating Officer at Ligand Pharmaceuticals Incorporated since April 2011 and also its the President since January 2015. At Ligand, Mr. Foehr is responsible for Ligand Pharmaceuticals's portfolio of more than 100 fully funded partnerships with the world's leading pharmaceutical companies across numerous technology types, therapeutic areas and drug targets. He served as Executive Vice President of Ligand Pharmaceuticals Incorporated from April 2011 to February 2015. He has more than 20 years of experience in the pharmaceutical industry, having managed global operations and research and development programs. Mr. Foehr served as Vice President, Head of Consumer Dermatology R&D and Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). He led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support and Vice President of Supply Chain Technical Services. Prior to Stiefel, he served as Senior Vice President, Technical Operations of Connetics Corporation since January 2003. Mr. Foehr joined Connetics in 1999 and served as its Vice President of Manufacturing from November 2001 to December 2002 and also held various Director and Manager-level manufacturing positions from July 1999 to November 2001. Mr. Foehr worked for over five years at LXR Biotechnology, Inc., including as Associate Director, Manufacturing and Process Development. Before joining LXR, he worked for Berlex Biosciences in the Department of Process Development and Biochemistry/Biophysics. Mr. Foehr has been a Director at Ritter Pharmaceuticals, Inc. since February 01, 2015 and Viking Therapeutics, Inc. since May 2014. He is the author of multiple scientific publications and is named on numerous U.S. patents. Mr. Foehr received his B.S. in Biology from Santa Clara University.